Retinal Biologics Market 2018 Announce Eminent CAGR Growth at (11.1%) until 2028 - PowerPoint PPT Presentation

About This Presentation
Title:

Retinal Biologics Market 2018 Announce Eminent CAGR Growth at (11.1%) until 2028

Description:

According to Prevent Blindness statistics, the prevalence of diabetic retinopathy in the U.S. is estimated to be 5.3%. VEGF-A antagonist is largely prescribed for the diabetic retinopathy treatment and also for treatment of diabetic macular edema. – PowerPoint PPT presentation

Number of Views:34
Slides: 11
Provided by: Umesh213
Category: Other

less

Transcript and Presenter's Notes

Title: Retinal Biologics Market 2018 Announce Eminent CAGR Growth at (11.1%) until 2028


1
Retinal Biologics Market
  • April 2020

Report Id REP-GB-8663 Published On
2019-01-25 Category Healthcare, Pharmaceuticals
Medical Devices
2
AboutFuture Market Insights
Future Market Insights (FMI) is a premier
provider of syndicated research reports, custom
research reports, and consulting services. We
deliver a complete packaged solution, which
combines current market intelligence, statistical
anecdotes, technology inputs, valuable growth
insights, aerial view of the competitive
framework, and future market trends. We provide
research services at a global as well as regional
level key regions include GCC, ASEAN,
and BRIC. Our offerings cover a broad spectrum of
industries including Chemicals, Materials,
Energy, Technology, Healthcare, and Retail. We
have a global presence with delivery centers
across India specializing in providing global
research reports and country research reports.
FMI is headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Research Capabilities
Sector Coverage
  • Customized Research
  • Syndicated Research
  • Investment Research
  • Social Media Research

  • Automotive and Transportation
  • Electronics, Semiconductor, and ICT
  • Retail and Consumer Products
  • Industrial Automation and Equipment
  • Chemicals Materials
  • Food and Beverages
  • Services and Utilities
  • Energy, Mining, Oil, and Gas

Subscription Information

For detailed subscription information please
contact Hari. T (Sr. Manager - Global Business
Development) T 44 (0) 20 7692 8790 D 44
20 3287 4268 Email hari.t_at_futuremarketinsights.co
m
3
Research Methodology (1/2)
  • Systematic Research Approach

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc.
FMI formulates a detailed discussion guide to conduct expert and industry interviews
FMI develops a list of industry players (manufacturers), distributors, retailers and industry experts
FMI conducts interviews with industry experts, industry players, distributors and retailers
Data is validated by triangulation method, wherein secondary, primary and FMI analysis contribute to the final data
Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry
FMI delivers industry insights and information in the required format (PDF)
  • Identifying key opinion leaders
  • Questionnaire design
  • In-depth interviews
  • Coverage across value chain
  • Key industry experts
  • Channel study
  • Developments
  • Market dynamics
  • Products
  • Conclusions

SOLUTION
  • Market participants
  • Key strengths
  • Product portfolio
  • Mapping as per value chain
  • Key focus segments

Primary Research
Secondary Research
Paid Publications
  • Linkedin
  • Zoominfo
  • Salesforce
  • Avention
  • Factiva
  • GBI
  • Genios
  • Meltwater
  • Company websites
  • Company annual reports
  • White papers
  • Financial reports

includes sources of databases
4
Retinal Biologics Market Analysis
  • Retinal biologics market value surpassed US 14.6
    billion in 2018 and projected to grow at 10.7
    y-o-y in 2019, as per a new FMI study. The
    projected growth of the market can be attributed
    to,
  • Increasing prevalence of diabetic eye diseases
    and age-related macular degeneration (AMD)
  • Significant RD investments engaged in developing
    biologics for infectious and non-infectious
    retinal diseases
  • Growing application of specific biologic
    molecules as a promising drug target
  • Development of gene therapy as retinal biologics
    in the wake of large number of monogenic retinal
    disorders
  • "Higher specificity of retinal biologics
    as compared to other traditional therapies has
    escalated RD efforts in the retinal drug
    delivery field. Rising burden of diseases as well
    as treatment on the back of ageing population and
    spread of diabetes epidemic have increased
    efforts in finding the cure of untreatable
    diseases. Greater strides to develop long-acting
    therapeutics in a bid to reduce disease burden is
    set to augur well for the retinal biologics
    market and generation of US 16.2 billion market
    value is projected in 2019," says FMI report.

5
Retinal Biologics Market Analysis
Promising Treatment of VEGF-A Antagonist Drug
Translates to Hefty Revenue Generation The FMI
study estimates that adoption of VEGF-A
antagonist class of drugs remains higher as
compared to TNF-a inhibitor. In 2018, VEGF-A
antagonist drugs witnessed significant
penetration while accounting for a hefty 93
revenues of the retinal biologics market.
Significant advances in developing biologics for
VEGF-A antagonist therapy and their delivery to
posterior ocular tissues are underway. Ubiquitous
acceptance of VEGF-A antagonist therapy has led
manufacturers to invest in the development of
retinal biologics in a similar area. For
instance, Eylea by Regeneron and Lucentis by
Roche are VEGF-A antagonist drugs available in
the market. The study finds that despite lower
revenues, penetration of TNF-a inhibitor drugs is
likely to increase at a rapid pace in the coming
years. In 2019, annual revenues of TNF-a
inhibitor drug class are expected to grow at an
impressive rate of 11.6.
6
Retinal Biologics Market Analysis
Retinal Biologics Find Prominent Use in Macular
Degeneration Treatment The study opines that
over 35 of the retinal biologics revenues were
consolidated in the treatment of macular
degeneration. Highest revenue growth of 12.3 is
also expected in macular degeneration as compared
to other indications where retinal biologics are
used in 2019. Macular degeneration (MD) remains
the leading cause of vision loss wherein it
affects over 10 million Americans, the prevalence
is higher than the combined incidences of
cataract and glaucoma, as per the American
Macular Degeneration Foundation (AMDF). As
macular degeneration mainly affect people of age
50 years or more, with the ageing population, the
prevalence of MD continues to rise despite
improved treatment options. Diabetic retinopathy
and diabetic macular edema treatments also
significantly include retinal biologics in
therapy. FMI shows that collectively both the
disorders accounted for over 43 of the retinal
biologics market revenues in 2018. Annual revenue
growth in these two disorders is estimated to
remain above 10 in 2019. Increasing incidences
of diabetes complications on the back of growing
epidemic of diabetes will continue to increase
cases of diabetic retinopathy and diabetic
macular edema, thereby generating demand for
retinal biologics in the coming years.
7
Retinal Biologics Market Analysis
Retinal Biologics Distribution in Specialty
Clinics and Hospitals Prominent Manufacturers in
the retinal biologics market distribute the
products through institutional and retail
distribution channels. The FMI study finds that
institutional sales will garner higher revenues
in the retinal biologics market wherein retinal
biologics are distributed in specialty clinics
and hospitals. Sales in hospitals accounted for
over 35 of the market revenues in 2018. The
study estimates that retail sales of retinal
biologics will garner similar revenues as that of
hospitals and grow at 11.9 in 2019. Retail
distribution occurs through retail pharmacies and
mail order pharmacies of which retail pharmacies
will register higher revenues as compared to its
counterparts in the coming years. Penetration in
North America Higher, APEJ's Attractiveness to
Increase North America continues to hold leading
revenues in the retinal biologics market.
According to FMI valuation, North America held
over 46 of the global retinal biologics market
revenues in 2018. Revenues in North America are
expected to grow at 10.4 y-o-y in 2019 on the
back of increasing prevalence of retinal
disorders, steady growth of the healthcare
infrastructure and favorable reimbursement
scenario.
8
Retinal Biologics Market Analysis
  • Europe garnered nearly one-fourth revenues in the
    retinal biologics market, wherein a bulk of
    demand penetration was observed in Western
    European countries such as Germany, the UK,
    France, Italy, Spain and others. The
    attractiveness of the APEJ retinal biologics
    market is expected to rise at the rate of 11 in
    2019, wherein China and India remain the most
    lucrative markets.
  • The FMI report tracks the retinal biologics
    market for the period 2018-2028. According to the
    report, the retinal biologics market is projected
    to grow at 11.1 CAGR through 2028.
  • Request for covid19 Impact Analysis
    https//www.futuremarketinsights.com/covid19/REP-G
    B-8663
  • Press Release Source https//www.prnewswire.com/n
    ews-releases/retinal-biologics-market-expected-to-
    increase-at-a-11-1-cagr-through-2028--future-marke
    t-insights-300789830.html
  • More from Healthcare, Pharmaceuticals and Medical
    devices Market Intelligence
  • Hearing Implants Market
  • Ophthalmic Lasers Market
  • Gastroesophageal Reflux Disease (GERD) Devices
    Market

9
Retinal Biologics Market Analysis
About Future Market Insights (FMI) Future Market
Insights (FMI) is a leading provider of market
intelligence and consulting services, serving
clients in over 150 countries. FMI is
headquartered in London, the global financial
capital, and has delivery centers in the U.S. and
India. FMIs largest market research reports and
industry analysis help businesses navigate
challenges and take critical decisions with
confidence and clarity amidst breakneck
competition. Contact Mr. Abhishek
Budholiya Unit No AU-01-H Gold Tower (AU), Plot
No JLT-PH1-I3A, Jumeirah Lakes Towers,
Dubai, United Arab Emirates MARKET ACCESS DMCC
Initiative For Sales Enquiries sales_at_futuremarket
insights.com For Media Enquiries press_at_futuremark
etinsights.com Future Market Insights
10
To know more about us, please visit our website
www.futuremarketinsights.com For sales queries
or new topics email us on sales_at_futuremarketinsi
ghts.com For media queries, contact the press
office at press_at_futuremarketinsights.com For
other queries contactHari. T (Sr. Manager -
Global Business Development) Future Market
Insights 3rd Floor,207 Regent Street, London
W1B 3HH T 44 20 7692 8790 D 44 20 3287
4268 Email hari.t_at_futuremarketinsights.com
Thank You
Future Market Insights Global Consulting
Private Limited (FMI)
Write a Comment
User Comments (0)
About PowerShow.com